Cellular Biomedicine Group (CBMG) Announces Annual Meeting of Stockholders
SHANGHAI, China and CUPERTINO, Calif., Mar. 21, 2017 — Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Annual Meeting of Stockholders will be held on Friday, April 28, 2017. The meeting will be held at the Company’s office at 19925 Stevens Creek Blvd., Suite 100, Cupertino, California 95014 at 9:00 a.m. PDT. Stockholders of record as of March 10, 2017, the record date for the meeting, are authorized and asked to vote in the manner directed in the proxy materials.
A stockholder, once having received his/her proxy notice and access card, may view the proxy statement and related materials online or request a printed copy at www.iproxydirect.com/CBMG. Stockholders may vote online, by mail or by phone, according to the instructions on the proxy, no later than 11:59pm, Thursday, April 27, 2017, EDT. If your shares are held in the name of a bank, broker or other nominee, please check with your bank, broker or nominee and follow the voting instructions it provides. Please send an email to email@example.com if you have questions about the Annual Meeting or have not received your proxy notice card by post or by email.
About Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit www.cellbiomedgroup.com.
Director of Corporate Communications, CBMG
Managing Director Investor Relations, Citigate Dewe Rogerson
+1 347 481-3711